Marker Therapeutics, Inc.

NasdaqCM:MRKR Stock Report

Market Cap: US$23.8m

Marker Therapeutics Management

Management criteria checks 3/4

Marker Therapeutics' CEO is Juan Vera, appointed in May 2023, has a tenure of 7.58 years. total yearly compensation is $681.38K, comprised of 61% salary and 39% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $382.07K. The average tenure of the management team and the board of directors is 2.7 years and 7.6 years respectively.

Key information

Juan Vera

Chief executive officer

US$681.4k

Total compensation

CEO salary percentage60.96%
CEO tenure3yrs
CEO ownership1.6%
Management average tenure2.7yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Analysis Article • Jan 12

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Oct 04

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 13

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Marker Therapeutics, Inc. (NASDAQ:MRKR), a biotech focused on T cell-based immunotherapies, announced Tuesday that the FDA awarded a $2M grant to support its Phase 2 ARTEMIS trial for liquid tumor candidate MT-401 in patients with post-transplant acute myeloid leukemia (AML). MRKR shares added ~10% in the pre-market trading in reaction. MRKR said that the funding awarded under FDA’s Orphan Products Grants program would support the company’s treatment arm designed to test MT-401 in patients with post-transplant AML with minimal residual disease. In 2020, the FDA granted Orphan Drug Designation for MT-401 for treating AML following the allogeneic stem cell transplant. FDA’s Orphan Products Grants program has supported studies that led to the approval of over 70 products. A drug classified as a multi-tumor-associated antigen (MultiTAA) T-cell therapy, MT-401, is currently undergoing the multicenter ARTEMIS trial in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting.
Seeking Alpha • Aug 11

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics press release (NASDAQ:MRKR): Q2 GAAP EPS of -$0.11 misses by $0.01. Revenue of $0.79M misses by $1.71M. “We are very optimistic about the ability of MT-401 to drive results for patients with measurable residual disease given the results we have seen to date in the ARTEMIS study,” said Dr. Mythili Koneru, Marker’s Chief Medical Officer. “Of note, we were very pleased to note that the second patient we treated with MRD+ disease was found to be MRD- by that patient’s week 8 follow-up. The ability to administer MT-401 without the need for lymphodepletion, coupled with our improved accelerated manufacturing process, enable us to treat patients who have MRD+ disease. We believe that the results observed to date support the notion that patients with AML would have meaningful benefit from a multi-antigen targeted T cell therapy approach.”
Analysis Article • Jun 17

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 04

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 19

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 22

Marker Therapeutics: Passing Through A Catalyst Desert

MRKR has been trading downwards and sideways for months now. I was asked to see if I can figure out why. It appears that there's a catalyst desert that's been taking its toll on the stock's performance.
Analysis Article • Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 22

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Every investor in Marker Therapeutics, Inc. ( NASDAQ:MRKR ) should be aware of the most powerful shareholder groups...
Analysis Article • Dec 29

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

CEO Compensation Analysis

How has Juan Vera's remuneration changed compared to Marker Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025n/an/a

-US$12m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$15m

Mar 31 2025n/an/a

-US$13m

Dec 31 2024US$400kUS$400k

-US$11m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$585kUS$399k

-US$14m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$582kUS$380k

-US$20m

Compensation vs Market: Juan's total compensation ($USD681.38K) is about average for companies of similar size in the US market ($USD638.05K).

Compensation vs Earnings: Juan's compensation has increased whilst the company is unprofitable.

CEO

Juan Vera (45 yo)

3yrs
Tenure
US$681,380
Compensation

Dr. Juan F. Vera, MD, serves as Chief Executive Officer and President at Marker Therapeutics, Inc. since May 1, 2023 and serves as its Secretary and Treasurer. He has held various positions at the Center f...

Leadership Team

NamePositionTenureCompensationOwnership
Juan Vera
Co-Founder3yrsUS$681.38k1.6%
$ 382.1k
Elizabeth Donnelly
Director of Administration9.7yrsno datano data
Maria-Bernadette Madel
Director of Corporate Operations & External Communications2.4yrsno datano data
Edmund Cheung
Vice President of Human Resources3.3yrsno datano data
Patricia Allison
Head of Clinical Operations2.3yrsno datano data
Mary Newman
Head of Regulatory Affairs2.3yrsno datano data
Robert Florkiewicz
Senior Director of Molecular Biology & Virologyno datano datano data
2.7yrs
Average Tenure
45yo
Average Age

Experienced Management: MRKR's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Juan Vera
Co-Founder7.6yrsUS$681.38k1.6%
$ 382.1k
Steven Elms
Independent Director6.8yrsUS$261.89k0.084%
$ 20.1k
Malcolm Brenner
Member of Scientific Advisory Board8.3yrsno datano data
Cliona Rooney
Member of Scientific Advisory Board8.3yrsno datano data
Kathryn Corzo
Independent Directorless than a yearUS$130.00kno data
Norman Eansor
Independent Chairman7.6yrsUS$308.39k0.022%
$ 5.3k
Helen Heslop
Member of Scientific Advisory Board8.3yrsno datano data
Katharine Knobil
Independent Director4.4yrsUS$269.89k0.00090%
$ 214.6
7.6yrs
Average Tenure
63yo
Average Age

Experienced Board: MRKR's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/22 22:21
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Marker Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yun ZhongBrean Capital Historical (Janney Montgomery)
Leah Rush CannBrookline Capital Markets
John NewmanCanaccord Genuity